8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Mar 24, 2026·SEC
Material company update
Jan 7, 2026·SEC
LENZ Therapeutics, Inc.(LENZ)Earnings, Financials & Key Ratios
LENZ•NASDAQ
Price updated Jun 19, 2026
AboutLENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Show more
- Revenue$19M
- EBITDA-$91M-55.2%
- Net Income-$82M-65.0%
- EPS (Diluted)-2.85-21.8%
- Gross Margin96.31%
- EBITDA Margin-475.96%
- Operating Margin-477.46%
- Net Margin-430.25%
- ROE-33.63%+62.4%
LENZ Key Insights
LENZ Therapeutics, Inc. (LENZ) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.6x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 4 (bottom 4%)
- ✗Shares diluted 35.4% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when LENZ posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LENZ Price & Volume
LENZ Therapeutics, Inc. (LENZ) stock price & volume — 10-year historical chart
Loading chart...
LENZ Growth Metrics
LENZ Therapeutics, Inc. (LENZ) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years8.37%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-128.31%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-103.39%
Return on Capital
10 Years-374.91%
5 Years-374.91%
3 Years-81.69%
Last Year-37.23%
LENZ Recent Earnings
LENZ Therapeutics, Inc. (LENZ) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 3/12 qtrs (75%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$1.32-20.0%
$1.10
Rev
$2M+8.1%
$2M
Q2 2026
Mar 24, 2026Metric
Actual
Est
EPS
$1.16-27.5%
$0.91
Rev
$2M-48.5%
$3M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.59+11.9%
$0.67
Rev
$13M+310.0%
$3M
Q3 2025
Jul 30, 2025Metric
Actual
Est
EPS
$0.53+8.6%
$0.58
Rev
$5M+600.0%
$714,286
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $1.32vs $1.10-20.0% | $2Mvs $2M+8.1% |
| Q2 2026 | Mar 24, 2026 | $1.16vs $0.91-27.5% | $2Mvs $3M-48.5% |
| Q4 2025 | Nov 5, 2025 | $0.59vs $0.67+11.9% | $13Mvs $3M+310.0% |
| Q3 2025 | Jul 30, 2025 | $0.53vs $0.58+8.6% | $5Mvs $714,286+600.0% |
Based on last 12 quarters of dataView full earnings history →
LENZ Peer Comparison
LENZ Therapeutics, Inc. (LENZ) competitors in Ophthalmology Therapies and Delivery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRPH | 355.28K | 0.08 | -0.04 | -35.82% | -339.31% | -157.67% | 2.46 | |
 KALA | 79.17M | 3.61 | -1.09 | -13.36% | ||||
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 AEYE | 78.83M | 6.31 | -25.24 | 14.52% | -9.05% | -70.95% | 2.75 | |
 AVXL | 252.99M | 2.73 | -5.06 | -38.76% | ||||
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 | |
 RXST | 195.81M | 4.73 | -4.98 | -3.89% | -36.58% | -17.01% | 0.04 | |
 ATRC | 1.46B | 28.80 | -120 | 14.88% | -0.83% | -0.95% | 0.18 |
Compare LENZ vs Peers
LENZ Therapeutics, Inc. (LENZ) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LENZ Income Statement
LENZ Therapeutics, Inc. (LENZ) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 15M | 0 | 0 | 19.09M | 20.99M |
Revenue Growth % | - | - | - | - | -100% | - | - | - |
Cost of Goods Sold | 0 | 121K | 734K | 0 | 0 | 58K | 705K | 1.86M |
COGS % of Revenue | - | - | - | - | - | - | 3.69% | - |
Gross Profit | 0▲ 0% | -121K▲ 0% | -734K▼ 506.6% | 15M▲ 2143.6% | 0▼ 100.0% | -58K▲ 0% | 18.38M▲ 31794.8% | 19.13M▲ 0% |
Gross Margin % | - | - | - | 100% | - | - | 96.31% | 91.16% |
Gross Profit Growth % | - | - | -506.61% | 2143.6% | -100% | - | 31794.83% | - |
Operating Expenses | 29K | 13.38M | 59.71M | 25.48M | 72.43M | 58.55M | 109.52M | 137.47M |
OpEx % of Revenue | - | - | - | 169.89% | - | - | 573.77% | - |
Selling, General & Admin | 29K | 4.26M | 21.78M | 4.36M | 12.93M | 28.75M | 90.85M | 124.62M |
SG&A % of Revenue | - | - | - | 29.05% | - | - | 475.96% | - |
Research & Development | 0 | 9.12M | 37.93M | 21.13M | 59.5M | 29.8M | 18.67M | 12.85M |
R&D % of Revenue | - | - | - | 140.83% | - | - | 97.81% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -29K▲ 0% | -13.5M▼ 46451.7% | -60.44M▼ 347.7% | -10.48M▲ 82.7% | -72.43M▼ 590.9% | -58.61M▲ 19.1% | -91.14M▼ 55.5% | -118.34M▲ 0% |
Operating Margin % | - | - | - | -69.89% | - | - | -477.46% | -563.83% |
Operating Income Growth % | - | -46451.72% | -347.73% | 82.66% | -590.92% | 19.08% | -55.5% | - |
EBITDA | 142.86K | -13.38M | -59.71M | -10.47M | -72.41M | -58.55M | -90.85M | -117.98M |
EBITDA Margin % | - | - | - | -69.83% | - | - | -475.96% | -562.1% |
EBITDA Growth % | - | -9465.11% | -346.29% | 82.46% | -591.3% | 19.14% | -55.16% | -98.74% |
D&A (Non-Cash Add-back) | 171.86K | 121K | 734K | 8K | 15K | 58K | 287K | 362K |
EBIT | -29K | -68.33M | -70.76M | -10.48M | -72.43M | -49.77M | -91.14M | -118.34M |
Net Interest Income | -80K | -40K | 0 | 0 | 2.19M | 8.55M | 9.76M | 10.08M |
Interest Income | 0 | 0 | 0 | 0 | 2.19M | 8.55M | 9.76M | 10.08M |
Interest Expense | 80K | 40K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -80K | -54.87M | -10.32M | 19K | 2.28M | 8.84M | 9.51M | 9.85M |
Pretax Income | -109K▲ 0% | -68.37M▼ 62627.5% | -70.76M▼ 3.5% | -10.46M▲ 85.2% | -70.15M▼ 570.4% | -49.77M▲ 29.1% | -81.63M▼ 64.0% | -108.49M▲ 0% |
Pretax Margin % | - | - | - | -69.76% | - | - | -427.62% | -516.91% |
Income Tax | 0 | 0 | 0 | 347K | -179K | 1K | 502K | 502K |
Effective Tax Rate % | 0% | 0% | 0% | -3.32% | 0.26% | -0% | -0.62% | -0.46% |
Net Income | -109K▲ 0% | -68.37M▼ 62627.5% | -70.76M▼ 3.5% | -10.81M▲ 84.7% | -69.97M▼ 547.2% | -49.77M▲ 28.9% | -82.13M▼ 65.0% | -109M▲ 0% |
Net Margin % | - | - | - | -72.07% | - | - | -430.25% | -519.3% |
Net Income Growth % | - | -62627.52% | -3.49% | 84.72% | -547.19% | 28.87% | -65.02% | -128.31% |
Net Income (Continuing) | -109K | -68.37M | -70.76M | -10.81M | -69.97M | -49.77M | -82.13M | -109M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.01▲ 0% | -8.24▼ 62800.8% | -8.54▼ 3.6% | -12.89▼ 51.0% | -15.30▼ 18.7% | -2.34▲ 84.7% | -2.85▼ 21.8% | -3.48▲ 0% |
EPS Growth % | - | -62800.76% | -3.62% | -50.97% | -18.69% | 84.71% | -21.79% | -103.39% |
EPS (Basic) | -0.01 | -8.24 | -8.54 | -12.89 | -15.30 | -2.34 | -2.85 | - |
Diluted Shares Outstanding | 8.3M | 8.3M | 8.29M | 7.84M | 8.15M | 21.28M | 28.81M | 31.35M |
Basic Shares Outstanding | 8.3M | 8.3M | 8.29M | 7.84M | 8.15M | 21.28M | 28.81M | 31.35M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
LENZ Balance Sheet
LENZ Therapeutics, Inc. (LENZ) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 6K | 21.1M | 18.32M | 46.64M | 67.24M | 211.92M | 292.35M | 268.37M |
Cash & Short-Term Investments | 6K | 19.82M | 18.31M | 44.44M | 65.79M | 209.03M | 292.35M | 258.38M |
Cash Only | 6K | 19.82M | 18.31M | 44.44M | 35.14M | 20.16M | 25.18M | 24.77M |
Short-Term Investments | 0 | 0 | 0 | 0 | 30.65M | 188.87M | 267.17M | 233.61M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 2.43M | 343K |
Days Sales Outstanding | - | - | - | - | - | - | 46.45 | 12.05 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.5M |
Days Inventory Outstanding | - | - | - | - | - | - | - | 218.64 |
Other Current Assets | 0 | 1.29M | 16K | 2.2M | 1.45M | 114K | -2.43M | 6.14M |
Total Non-Current Assets | 0 | 1.46M | 12K | 310K | 3.13M | 3.39M | 13.53M | 4.17M |
Property, Plant & Equipment | 0 | 1.46M | 10K | 279K | 372K | 1.99M | 0 | 1.72M |
Fixed Asset Turnover | - | - | - | 53.76x | - | - | - | 14.11x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 2K | 31K | 2.76M | 1.4M | 13.53M | 2.45M |
Total Assets | 6K▲ 0% | 22.56M▲ 375966.7% | 18.34M▼ 18.7% | 46.95M▲ 156.1% | 70.38M▲ 49.9% | 215.3M▲ 205.9% | 305.88M▲ 42.1% | 272.54M▲ 0% |
Asset Turnover | - | - | - | 0.32x | - | - | 0.06x | 0.08x |
Asset Growth % | - | 375966.67% | -18.74% | 156.07% | 49.89% | 205.93% | 42.07% | 78.8% |
Total Current Liabilities | 2.22M | 32.05M | 1.25M | 9.5M | 18.51M | 10.41M | 21.19M | 25.81M |
Accounts Payable | 0 | 630K | 460K | 4.75M | 5.71M | 4.26M | 4.17M | 10.93M |
Days Payables Outstanding | - | 1.9K | 228.75 | - | - | 26.79K | 2.16K | 1.1K |
Short-Term Debt | 2.21M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 19K | 30.95M | 0 | 0 | 0 | 0 | 17.02M | 14.88M |
Current Ratio | 0.00x | 0.66x | 14.62x | 4.91x | 3.63x | 20.36x | 13.80x | 10.40x |
Quick Ratio | 0.00x | 0.66x | 14.62x | 4.91x | 3.63x | 20.36x | 13.80x | 10.26x |
Cash Conversion Cycle | - | - | - | - | - | - | - | -864.36 |
Total Non-Current Liabilities | 0 | 316K | 31.3M | 61.62M | 144.57M | 814K | 350K | 237K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 350K | 237K |
Capital Lease Obligations | 0 | 0 | 0 | 147K | 192K | 814K | 0 | 569K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 316K | 31.3M | 61.47M | 144.38M | 0 | 0 | 0 |
Total Liabilities | 2.22M | 32.36M | 32.55M | 71.12M | 163.09M | 11.22M | 21.54M | 26.04M |
Total Debt | 2.21M | 0 | 0 | 250K | 329K | 1.38M | 350K | 237K |
Net Debt | 2.2M | -19.82M | -18.31M | -44.19M | -34.81M | -18.78M | -24.83M | -24.54M |
Debt / Equity | - | - | - | - | - | 0.01x | 0.00x | 0.00x |
Debt / EBITDA | 15.43x | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | 15.39x | - | - | - | - | - | - | 0.21x |
Interest Coverage | -0.36x | -1708.33x | - | - | - | - | - | - |
Total Equity | -2.22M▲ 0% | -9.8M▼ 341.8% | -14.21M▼ 45.0% | -24.17M▼ 70.0% | -92.71M▼ 283.6% | 204.08M▲ 320.1% | 284.34M▲ 39.3% | 246.49M▲ 0% |
Equity Growth % | - | -341.84% | -45.04% | -70.04% | -283.6% | 320.13% | 39.32% | 64.75% |
Book Value per Share | -0.27 | -1.18 | -1.72 | -3.08 | -11.38 | 9.59 | 9.87 | 7.86 |
Total Shareholders' Equity | -2.22M | -9.8M | -14.21M | -24.17M | -92.71M | 204.08M | 284.34M | 246.49M |
Common Stock | 0 | 0 | 1K | 10K | 10K | 1K | 1K | 1K |
Retained Earnings | -2.22M | -70.59M | -14.47M | -25.28M | -95.25M | -145.01M | -227.14M | -268.63M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 6K | 196K | 242K | -450K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LENZ Cash Flow Statement
LENZ Therapeutics, Inc. (LENZ) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -19K | -8.72M | -52.85M | -87.98M | -60.38M | -59.39M | -69.17M | -86.7M |
Operating CF Margin % | - | - | - | -586.53% | - | - | -362.37% | - |
Operating CF Growth % | - | -45800% | -506.03% | -66.46% | 31.37% | 1.64% | -16.47% | -327.06% |
Net Income | -109K | -68.37M | -70.76M | -101.05M | -69.97M | -49.77M | -82.13M | -109M |
Depreciation & Amortization | 0 | 121K | 734K | 8.35M | 15K | 58K | -3.12M | -3.05M |
Stock-Based Compensation | 0 | 0 | 0 | 0 | 1.34M | 6.37M | 12.55M | 9.99M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 80K | 57.82M | 19.67M | 11.93M | -1.18M | -2.95M | 279K | 5.75M |
Working Capital Changes | 10K | 1.71M | -2.5M | -7.21M | 9.41M | -13.09M | 3.25M | 9.6M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | -329K | -14K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | -4.28M | -4.21M |
Change in Payables | -12K | 594K | 1.82M | 194K | 856K | -4.28M | -90K | 7.44M |
Cash from Investing | 0 | -1.54M | -5.74M | -241.86M | -29.62M | -154.48M | -75.67M | -61.4M |
Capital Expenditures | 0 | -1.54M | -5.74M | -6.59M | -30K | -468K | -827K | -735K |
CapEx % of Revenue | - | - | - | 43.96% | - | - | 4.33% | 3.5% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 0 | 30.08M | 417.47M | 597K | 80.7M | 199M | 149.75M | 149.72M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 30.08M | 417.16M | 597K | 82.98M | 79.51M | 149.75M | 149.29M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -79K | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 306K | 0 | -2.28M | 119.49M | 0 | 421K |
Net Change in Cash | 6K▲ 0% | 19.81M▲ 330083.3% | 357.16M▲ 1702.8% | -329.25M▼ 192.2% | -9.3M▲ 97.2% | -14.87M▼ 59.9% | 4.91M▲ 133.0% | 1.62M▲ 0% |
Free Cash Flow | -19K▲ 0% | -10.27M▼ 53931.6% | -58.59M▼ 470.7% | -94.57M▼ 61.4% | -60.41M▲ 36.1% | -59.86M▲ 0.9% | -70M▼ 16.9% | -87.44M▲ 0% |
FCF Margin % | - | - | - | -630.49% | - | - | -366.71% | -416.59% |
FCF Growth % | - | -53931.58% | -470.74% | -61.41% | 36.12% | 0.91% | -16.94% | -67.89% |
FCF per Share | -0.00 | -1.24 | -7.07 | -12.06 | -7.42 | -2.81 | -2.43 | -2.79 |
FCF Conversion (FCF/Net Income) | 0.17x | 0.13x | 0.75x | 8.14x | 0.86x | 1.19x | 0.84x | 0.80x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LENZ Key Ratios
LENZ Therapeutics, Inc. (LENZ) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | - | - | -89.37% | -33.63% | -46.82% |
Return on Invested Capital (ROIC) | - | - | - | - | -152.14% | -30.73% | -43.28% |
Gross Margin | - | - | 100% | - | - | 96.31% | 91.16% |
Net Margin | - | - | -72.07% | - | - | -430.25% | -519.3% |
Debt / Equity | - | - | - | - | 0.01x | 0.00x | 0.00x |
Interest Coverage | -1708.33x | - | - | - | - | - | - |
FCF Conversion | 0.13x | 0.75x | 8.14x | 0.86x | 1.19x | 0.84x | 0.80x |
Revenue Growth | - | - | - | -100% | - | - | - |
Related:LENZ Dividend History·LENZ Revenue History·LENZ Price History·LENZ P/E History·LENZ Financial Ratios·LENZ Institutional Holders
LENZ SEC Filings & Documents
LENZ Therapeutics, Inc. (LENZ) SEC filings — annual & quarterly reports (10-K, 10-Q)
LENZ Frequently Asked Questions
LENZ Therapeutics, Inc. (LENZ) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
LENZ Therapeutics, Inc. (LENZ) reported $21.0M in revenue for fiscal year 2025.
LENZ Therapeutics, Inc. (LENZ) grew revenue by 0.0% over the past year. Growth has been modest.
LENZ Therapeutics, Inc. (LENZ) reported a net loss of $109.0M for fiscal year 2025.
Dividend & Returns
LENZ Therapeutics, Inc. (LENZ) has a return on equity (ROE) of -33.6%. Negative ROE indicates the company is unprofitable.
LENZ Therapeutics, Inc. (LENZ) had negative free cash flow of $87.4M in fiscal year 2025, likely due to heavy capital investments.